Pergolide associated valvulopathy: Critical analysis of the literature and practical recommendations;Valvulopathies sous pergolide: Revue critique de la littérature et conduite à tenir en pratique

Revue Neurologique

Volumn 161, Issue 6-7, 2005, Pages 637-643

  Corvol, J C ^a   Schupbach M ^a   Bonnet, A M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Heart valve diseases; Parkinson's disease; Pergolide

Indexed keywords

FENFLURAMINE; PERGOLIDE; SEROTONIN 2B RECEPTOR;

CLINICAL PRACTICE; DISEASE SEVERITY; FIBROSIS; HUMAN; INCIDENCE; MEDICAL LITERATURE; MITRAL VALVE DISEASE; PARKINSON DISEASE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

EID: 21644477054     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85103-3     Document Type: Review

References (25)

1. AUSTIN SM, EL HAYAK A, COMIANOS N, TAMULONIS DJ. (1993). Mitral valve disease associated with long term ergotamine use. South Med J, 86: 1179-1181.
2. BANA DS, MACNEAL PS, LECOMPTE PM, SHAH Y, GRAHAM JR. (1974). Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J, 88: 640-655.
3. BASEMAN DG, O'SUILLEABHAIN PE, REIMOLD SC, LASKAR SR, BASEMAN JG, DEWEY RB JR. (2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology, 63: 301-304.
4. BEGAUD B, EVREUX JC, JOUGLARD J, LAGIER G. (1985). [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie, 40: 111-118.
5. CALOMNE V, DUPUIS MJ, MULLER T, KEMPINERE F. (2004). Valvulopathie réversible et traitement par pergolide. Rev Neurol (Paris), 160: 81-82.
6. CANESI M, ANTONINI A, MARIANI CB, TESEI S, ZECCHINELLI AL, BARICHELLA M, PEZZOLI G. (1999). An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. J Neural Transm, 106: 925-929.
7. FITZGERALD LW, BURN TC, BROWN BS et al. (2000). Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopâthy associated with fenfluramine. Mol Pharmacol, 57: 75-81.
8. FLOWERS CM, RACOOSIN JA, LU SL, BEITZ JG. (2003). The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc, 78: 730-731.
9. GOETZ CG, BLASUCCI L, STEBBINS GT. (1999). Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology, 52: 1227-1229.
10. HOBSON DE, POURCHER E, MARTIN WR. (1999). Ropinirole and pramipexole, the new agonists. Can J Neurol Sci, 26 (Suppl 2): S27-33.
11. HORVATH J, FROSS RD, KLEINER-FISMAN G et al. (2004). Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord, 19: 656-662.
12. JOST WH. (1999). Equivalent doses of ropinirole and bromocriptine. Eur J Neurol, 6: 618.
13. MASON JW, BILLINGHAM ME, FREIDMAN JP. (1977). Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation, 56: 889-890.
14. MILLAN MJ, MAIOFISS L, CUSSAC D, AUDINOT V, BOUTIN JA, NEWMAN-TANCREDI A. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303: 791-804.
15. MISCH KA. (1974). Development of heart valve lesions during methysergide therapy. BMJ, 2: 365-366.
16. MONTASTRUC JL, PATHAK A, BAGHERI H. (2004). Valvulopathies sous pergolide: la saga des fibroses dues aux dérivés de l'ergot de seigle continue! Rev Neurol (Paris), 160: 19-21.
17. PRITCHETT AM, MORRISON JF, EDWARDS WD, SCHAFF HV, CONNOLLY HM, ESPINOSA RE. (2002). Valvular heart disease in patients taking pergolide. Mayo Clin Proc, 77: 1280-1286.
18. RAHIMTOOLA SH. (2002). Drug-related valvular heart disease: here we go again: will we do better this time? Mayo Clin Proc, 77: 1275-1277.
19. RASCOL O, PATHAK A, BAGHERI H, MONTASTRUC JL. (2004). New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord, 19: 611-613.
20. REDFIELD MM, NICHOLSON WJ, EDWARDS WD, TAJIK AJ. (1992). Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med, 117: 50-52.
21. ROTHMAN RB, BAUMANN MH, SAVAGE JE, RAUSER L, MCBRIDE A, HUFEISEN SJ, ROTH BL. (2000). Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications. Circulation, 102: 2836-2841.
22. SERRATRICE J, DISDIER P, HABIB G, VIALLET F, WEILLER PJ. (2002). Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev, 10: 334-336.
23. SINGH JP, EVANS JC, LEVY D et al. (1999). Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol, 83: 897-902.
24. VAN CAMP G, FLAMEZ A, COSYNS B, GOLDSTEIN J, PERDAENS C, SCHOORS D. (2003). Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology, 61: 859-861.
25. VAN CAMP G, FLAMEZ A, COSYNS B et al. (2004). Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 363: 1179-1183.